MedTrace Logo

Cytokines in Blister Fluids of Bullous Pemphigoid (BP)

NCT03856840 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2019-10-04

No results posted yet for this study

Summary

This study investigates the differences of Eosinophil Cationic Protein, Tumor Necrosis Factor-alpha and Anti-BP180-NC16A IgG levels of blister fluids in Bullous Pemphigoid patients which appeared before and under treatment subsequently. These molecules will also be measured in blood serum before and under treatment. Changes of titers in serum and differences between blister fluids will be compared to observe whether correlation exists between them. These measures will also be compared between groups of responders and non-responders to the first-line treatment options to analyze correlation with treatment success.

Conditions

  • Pemphigoid, Bullous

Sponsors & Collaborators

  • Mahmut Can Koska

    lead OTHER

Principal Investigators

  • Mehmet Salih Gurel, Professor · Istanbul Medeniyet University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-29
Primary Completion
2019-05-23
Completion
2019-08-27

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03856840 on ClinicalTrials.gov